RxDoctor Payments DataLook up a doctor →

Aaron Elswood, PA

Physician Assistant · Lehi, UTNPI 1275619975

Payments from drug & device makers

$7,574in general payments, 2019–2025

Across 455 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$447
  • Astellas Pharma US Inc$441
  • Lilly USA, LLC$397
  • Boehringer Ingelheim$350
  • Tris Pharma Inc$297
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,39898%
  • Education$1762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie111$1,607
AstraZeneca28$447
Astellas Pharma US Inc17$441
Lilly USA, LLC25$397
Boehringer Ingelheim17$350
Tris Pharma Inc16$297
Corium, LLC14$240
Amgen14$228
Novo Nordisk13$205
Supernus Pharmaceuticals, Inc.12$204
Pfizer12$179
Corcept Therapeutics7$163
Johnson & Johnson7$160
Mylan Specialty L.p.5$129
Sanofi-aventis U.S. LLC9$125
Axsome Therapeutics, Inc.5$106
GSK7$98
Xeris Pharmaceuticals, Inc.5$97
Phathom Pharmaceuticals, Inc.7$95
Merck6$89
Abbott4$85
Otsuka America Pharmaceutical, Inc.5$85
Antares Pharma, Inc.6$83
Bayer5$82
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$79
Takeda Pharmaceuticals U.S.A., Inc.5$75
Kowa Pharmaceuticals America, Inc.5$73
Dexcom, Inc.4$71
Idorsia Pharmaceuticals US Inc4$68
Ironshore Pharmaceuticals Inc.4$67
Daiichi Sankyo Inc.3$65
Edwards Lifesciences3$57
Neuronetics, Inc.1$56
Boston Scientific3$50
Amarin Pharma, Inc.3$50
Avanir Pharmaceuticals, Inc.3$47
Almatica Pharma LLC3$47
Clarus Therapeutics Inc.3$43
Medtronic2$39
Biohaven Pharmaceutical Holding Company Ltd.2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$36
Collegium Pharmaceutical, Inc.2$35
Nestle Healthcare Nutrition Inc.2$33
Aimmune Therapeutics, Inc.2$33
Exact Sciences2$32
Alnylam Pharmaceuticals Inc.2$30
Cranial Technologies, Inc2$30
Organon4$30
Biohaven Pharmaceuticals, Inc.2$29
Mannkind Corporation1$28
Dynavax Technologies Corporation2$27
Sumitomo Pharma America, Inc.2$27
Adlon Therapeutics L.p.2$26
Mayne Pharma Commercial LLC1$26
Eisai Inc.2$24
Novartis1$22
Viatris Specialty LLC1$22
Vanda Pharmaceuticals Inc.1$21
Jazz Pharmaceuticals Inc.1$17
Hologic Sales And Service, LLC1$16

How this compares

$7,574 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$51,294
Medicare patients
128
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$63,783
MounjaroTirzepatide38$63,755
JardianceEmpagliflozin30$26,656
EliquisApixaban24$26,273
FarxigaDapagliflozin Propanediol22$16,348
MyrbetriqMirabegron13$15,509
XareltoRivaroxaban20$12,527
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,111
Repatha SureclickEvolocumab16$9,158
Repatha SyringeEvolocumab11$8,424
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$8,411
Xigduo XrDapaglifloz Propaned/Metformin20$7,458
TrintellixVortioxetine Hydrobromide11$6,266
LinzessLinaclotide11$5,720
OxycontinOxycodone Hcl13$4,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$63,78342 claims
Lilly USA, LLCMounjaro$397$63,75538 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$447$31,21153 claims
Boehringer IngelheimJardiance$350$26,65630 claims
PfizerEliquis$179$26,27324 claims
Astellas Pharma US IncMyrbetriq$441$15,50913 claims
Johnson & JohnsonXarelto$160$12,52720 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$75$6,26611 claims
AbbVieLinzess$1,607$5,72011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →